Alkem Laboratories Limited

NSE ALKEM.NS

Alkem Laboratories Limited Gross Profit Margin for the year ending March 31, 2024: 41.28%

Alkem Laboratories Limited Gross Profit Margin is 41.28% for the year ending March 31, 2024, a -28.45% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Alkem Laboratories Limited Gross Profit Margin for the year ending March 31, 2023 was 57.70%, a -2.63% change year over year.
Alkem Laboratories Limited Gross Profit Margin for the year ending March 31, 2022 was 59.25%, a 0.58% change year over year.
Alkem Laboratories Limited Gross Profit Margin for the year ending March 31, 2021 was 58.91%, a 1.85% change year over year.
Alkem Laboratories Limited Gross Profit Margin for the year ending March 31, 2020 was 57.84%, a 0.37% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NSE: ALKEM.NS

Alkem Laboratories Limited

CEO	Dr. Vikas Gupta
IPO Date	Dec. 23, 2015
Location	India
Headquarters	Devashish Building
Employees	17,432
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Key trends

Past 5 years